EUCTR2013-000048-24-HU
Active, not recruiting
Not Applicable
Randomised clinical trial evaluating the safety and effectiveness of esmolol and metoprolol for heart rate control of patients referred to coronary CT angiography
Hear Center of Semmelweis University0 sitesApril 3, 2013
ConditionsHeart rate control of patients referred to coronary computed tomography angiography (CCTA) due to suspected coronary artery disease are to investigated with esmolol and metoprolol. Acquiring diagnostic image quality with CCTA requires relative low and stable heart rate of the patients during examination. Thus, heart rate control with beta-blocker medication (esmolol, metoprolol) is recommended. However no current guideline is available regarding esmolol administration during CCTA.MedDRA version: 14.1Level: PTClassification code 10011078Term: Coronary artery diseaseSystem Organ Class: 10007541 - Cardiac disordersTherapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Heart rate control of patients referred to coronary computed tomography angiography (CCTA) due to suspected coronary artery disease are to investigated with esmolol and metoprolol. Acquiring diagnostic image quality with CCTA requires relative low and stable heart rate of the patients during examination. Thus, heart rate control with beta-blocker medication (esmolol, metoprolol) is recommended. However no current guideline is available regarding esmolol administration during CCTA.
- Sponsor
- Hear Center of Semmelweis University
- Status
- Active, not recruiting
- Last Updated
- 13 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •\- Age between 18\-90 years
- •\- Clinical indication of coronary computed tomography angiography
- •\- Understood of patient information form and given written consent
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1\.2 Adults (18\-64 years) yes
- •F.1\.2\.1 Number of subjects for this age range 400
- •F.1\.3 Elderly (\>\=65 years) yes
- •F.1\.3\.1 Number of subjects for this age range 100
Exclusion Criteria
- •\- Any clinical contraindication of coronary computed tomography angiography
- •\- Any clinical contraindication of beta\-blocker drug administration
- •\- Atrial fibrillation, atrial flutter within three months prior to examination or frequent irregular, high heart rate
- •\- implanted pacemaker or implanted cardioverter defibrillator
- •\- acute heart faiure, or known non\-ischemic cardiomyopathy
- •\- pregnancy
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not yet recruiting
Phase 2
se of Olaparib, a drug that inhibits an enzyme linked to inflammatory response and DNA repair, in sepsisRBR-8xdc8yzEscola Paulista de Medicina, Universidade Federal de São Paulo
Recruiting
Not Applicable
Randomized-controlled trial to assess the safety and efficacy of preoperative chemotherapy in patients with locally advanced colon cancerNeoplasmsKCT0003077Kyungpook National University Medical Center708
Recruiting
Not Applicable
A randomized clinical trial to evaluate the safety and effectiveness of the full-veneer crown fabricated with a 3D printed resin material for definitive prosthesisCodes for special purposesKCT0006081Yonsei University Health System, Dental Hospital60
Active, not recruiting
Not Applicable
Randomized trial to assess efficacy and safety of an add-on treatment with zonisamide in adults with focal epileptic seizures with or without secondary generalizatioPartial epileptic seizures with or without secondary generalisationMedDRA version: 7.1Level: PTClassification code 10040703EUCTR2005-000260-57-DEEisai GmbH
Not yet recruiting
Not Applicable
ength of nasogastric tube(Ryles tube) will be increased by 10 cm during insertion in patients with acute poisoning for evacuation of poison.Health Condition 1: T600- Toxic effect of organophosphate and carbamate insecticidesHealth Condition 2: T600- Toxic effect of organophosphate and carbamate insecticidesCTRI/2019/05/018914PGIMER Chandigarh